{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:26:27Z","timestamp":1793107587479,"version":"4.5.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To identify the incidence and timing of venous thromboembolism as well as any associated risk factors in patients with ovarian, fallopian tube, or primary peritoneal cancer undergoing neoadjuvant chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study of patients diagnosed with ovarian, fallopian tube, and primary peritoneal cancer and receiving neoadjuvant chemotherapy from January 2009 to May 2014 at a single academic institution. The timing and number of venous thromboembolic events for the entire cohort were categorized as follows: presenting symptom, during neoadjuvant chemotherapy treatment, after debulking surgery, and during adjuvant chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Of the 125 total patients with ovarian cancer undergoing neoadjuvant chemotherapy, 13 of 125 patients (10.4%, 95% confidence interval [CI] 6.1\u201317.2%) had a venous thromboembolism as a presenting symptom and were excluded from further analysis. Of the 112 total patients at risk, 30 (26.8%, 95% CI 19.3\u201335.9%) experienced a venous thromboembolism. Based on the phase of care, 13 (11.6%, 95% CI 6.8\u201319.1%) experienced a venous thromboembolism during neoadjuvant chemotherapy, six (5.4%, 95% CI 2.4\u201311.5%) developed a postoperative venous thromboembolism, and 11 (9.9%, 95% CI 5.5\u201317%) developed a venous thromboembolism during adjuvant chemotherapy. Two of the four patients with clear cell histology developed a venous thromboembolism in this cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Overall new diagnosis of venous thromboembolism was associated with one fourth of the patients undergoing neoadjuvant chemotherapy for ovarian cancer with nearly half of these diagnosed during chemotherapy cycles before interval debulking surgery. Efforts to reduce venous thromboembolism so far have largely focused on the postoperative period. Additional attention to venous thromboembolic prophylaxis during chemotherapy (neoadjuvant and adjuvant) in this patient population is warranted in an effort to decrease the rates of venous thromboembolism.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000001980","type":"journal-article","created":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T10:47:36Z","timestamp":1494326856000},"page":"979-985","source":"Crossref","is-referenced-by-count":56,"title":["Incidence and Timing of Thromboembolic Events in Patients With Ovarian Cancer Undergoing Neoadjuvant Chemotherapy"],"prefix":"10.1097","volume":"129","author":[{"given":"Patricia S.","family":"Greco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali A.","family":"Bazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"McLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Kevin","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn M.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Rebecca","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shitanshu","family":"Uppal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230711","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejogrb.2013.06.004","article-title":"Venous thromboembolism in ovarian cancer: incidence, risk factors and impact on survival","volume":"170","author":"Abu Saadeh","year":"2013","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R2-20230711","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3802\/jgo.2013.24.1.52","article-title":"Effect of ovarian tumor characteristics on venous thromboembolic risk","volume":"24","author":"Bakhru","year":"2013","journal-title":"J Gynecol Oncol"},{"key":"R3-20230711","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/bjc.2014.3","article-title":"Thrombosis in ovarian cancer: a case-control study","volume":"110","author":"Metcalf","year":"2014","journal-title":"Br J Cancer"},{"key":"R4-20230711","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11239-015-1318-z","article-title":"Guidance for the use of thrombolytic therapy for the treatment of venous thromboembolism","volume":"41","author":"Vedantham","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"R5-20230711","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ygyno.2012.08.032","article-title":"Prolonged postoperative venous thromboembolism prophylaxis is cost-effective in advanced ovarian cancer patients","volume":"127","author":"Uppal","year":"2012","journal-title":"Gynecol Oncol"},{"key":"R6-20230711","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ygyno.2012.11.027","article-title":"Venous thromboembolism (VTE) rates following the implementation of extended duration prophylaxis for patients undergoing surgeries for gynecologic malignancies","volume":"128","author":"Schmeler","year":"2013","journal-title":"Gynecol Oncol"},{"key":"R7-20230711","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/IGC.0000000000000164","article-title":"Venous thromboembolism in advanced ovarian cancer patients undergoing frontline adjuvant chemotherapy","volume":"24","author":"Pant","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"R9-20230711","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1016\/j.ejca.2013.06.013","article-title":"Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organization for Research and Treatment of Cancer 55971 randomized trial","volume":"49","author":"van Meurs","year":"2013","journal-title":"Eur J Cancer"},{"key":"R10-20230711","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jbi.2015.05.003","article-title":"Supporting information retrieval from electronic health records: a report of University of Michigan's nine-year experience in developing and using the Electronic Medical Record Search Engine (EMERSE)","volume":"55","author":"Hanauer","year":"2015","journal-title":"J Biomed Inform"},{"key":"R11-20230711","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jbi.2012.10.006","article-title":"Procurement of shared data instruments for Research Electronic Data Capture (REDCap)","volume":"46","author":"Obeid","year":"2013","journal-title":"J Biomed Inform"},{"key":"R12-20230711","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"R13-20230711","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"Charlson","year":"1994","journal-title":"J Clin Epidemiol"},{"issue":"suppl 2","key":"R14-20230711","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0049-3848(14)50006-0","article-title":"Risk stratification strategies for cancer-associated thrombosis: an update","volume":"133","author":"Khorana","year":"2014","journal-title":"Thromb Res"},{"key":"R15-20230711","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.thromres.2014.09.016","article-title":"Screening high-risk cancer patients for VTE: a prospective observational study","volume":"134","author":"Khorana","year":"2014","journal-title":"Thromb Res"},{"key":"R16-20230711","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/AOG.0000000000000822","article-title":"Risk factors for venous thromboembolism after hysterectomy","volume":"125","author":"Swenson","year":"2015","journal-title":"Obstet Gynecol"},{"key":"R18-20230711","first-page":"e1021818","article-title":"Characteristic and prognostic implication of venous thromboembolism in ovarian clear cell carcinoma: a 12-year retrospective study","volume":"10","author":"Ye","year":"2015","journal-title":"PLoS One"},{"key":"R19-20230711","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/dote.12084","article-title":"Venous thromboembolism in patients receiving perioperative chemotherapy for esophageal cancer","volume":"27","author":"Khanna","year":"2014","journal-title":"Dis Esophagus"},{"key":"R20-20230711","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/0284186X.2012.689114","article-title":"Incidence of thromboembolic events in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy","volume":"52","author":"Mezi","year":"2013","journal-title":"Acta Oncol"},{"key":"R21-20230711","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ygyno.2016.09.002","article-title":"Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States","volume":"143","author":"Melamed","year":"2016","journal-title":"Gynecol Oncol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006250-201706000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T14:18:51Z","timestamp":1689085131000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006250-201706000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000001980","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}